Midol Extended Relief and Toremifene Citrate

• Generic Name: naproxen
• Dosage Forms: n.a.
• Other Brand Names: Aleve, Anaprox-DS, Flanax Pain Reliever, Midol Extended Relief, Naprelan 500, Naprosyn, EC-Naprosyn, Naprelan 375, Flanax, Naprelan, Anaprox, Naproxen Sodium, Aleve Caplet, Aleve Gelcap, Aleve Easy Open Arthritis

Midol Extended Relief is a nonsteroidal anti-inflammatory drug (NSAID).

Midol Extended Relief is used to treat pain or inflammation caused by conditions such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps.

The delayed-release or extended-release tablets are slower-acting forms of naproxen that are used only for treating chronic conditions such as arthritis or ankylosing spondylitis. These forms of naproxen will not work fast enough to treat acute pain.

Midol Extended Relief may also be used for purposes not listed in this medication guide.

• Generic Name: toremifene
• Dosage Forms: n.a.
• Other Brand Names: Fareston

Palliative treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or estrogen-receptor unknown tumors (designated an orphan drug by FDA for this use). Not recommended for treatment of estrogen-receptor negative breast tumors. Similar efficacy and toxicity as tamoxifen. Not known whether toremifene offers a therapeutic advantage over tamoxifen for the treatment of advanced breast cancer in eligible patients.

Under investigation for use as adjuvant therapy for early-stage breast cancer in node-positive postmenopausal women. Results from trials to date suggest similar efficacy and toxicity as tamoxifen.

Efficacy in treatment of advanced breast cancer in men not demonstrated.

Because of demonstrated cross-resistance with tamoxifen, usefulness of toremifene as second-line endocrine therapy for treatment of metastatic breast cancer refractory to tamoxifen appears to be limited.

Under investigation as a preventive agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.